Allena Pharmaceuticals develops and commercializes non-systemic protein therapeutics to treat metabolic and orphan diseases.
Allena Pharmaceuticals has raised $2.8M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in May 2022.
Allena Pharmaceuticals's investors include Bessemer Venture Partners, Wellington Management, Fidelity, Third Rock Ventures, Frazier Healthcare Partners.
Allena Pharmaceuticals is headquartered in Newton, United States.
Allena Pharmaceuticals develops and commercializes non-systemic protein therapeutics to treat metabolic and orphan diseases.
Allena Pharmaceuticals is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Allena Pharmaceuticals — Funding & Investors." VCBacked, May 4, 2022, https://www.vcbacked.co/company/allena-pharmaceuticals. Accessed September 29, 2026.
VCBacked. (2022). Allena Pharmaceuticals — Funding & Investors. Retrieved September 29, 2026, from https://www.vcbacked.co/company/allena-pharmaceuticals
{{cite web |title=Allena Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/allena-pharmaceuticals |website=VCBacked |access-date=September 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated